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 Summary 
Multileaf collimator tracking has been implemented for the first time in a prospective 
prostate cancer clinical trial. Dose reconstruction was performed for 475 treatment 
fractions for 15 patients. 
Comparison of patients’ original planned dose with the calculated treated dose with 
and without MLC tracking demonstrates that implementation of MLC tracking results 
in a higher agreement between delivered and planned doses. The implications are 
potentially improved patient outcomes and more reliable radiobiological parameter 
determination. 
 
 
  
  
Abstract 
 
Purpose: To test the hypothesis that multileaf collimator (MLC) tracking improves 
the consistency between the planned and delivered dose compared with the dose 
without MLC tracking, in the setting of a prostate cancer volumetric modulated arc 
therapy trial. 
Methods and Materials: Multileaf collimator tracking was implemented for 15 
patients in a prostate cancer radiation therapy trial; in total, 513 treatment fractions 
were delivered. During each treatment fraction, the prostate trajectory and treatment 
MLC positions were collected. These data were used as input for dose 
reconstruction (multiple isocenter shift method) to calculate the treated dose (with 
MLC tracking)  and the dose that would have been delivered had MLC tracking not 
been applied (without MLC tracking). The percentage difference from planned for 
target and normal tissue dose-volume points were calculated. The hypothesis was 
tested for each dose-volume value via analysis of variance using the F test. 
Results: Of the 513 fractions delivered, 475 (93%) were suitable for analysis. 
The mean difference and standard deviation between the planned and treated 
MLC tracking doses and the planned and without-MLC tracking doses for all 475 
fractions were,  respectively,  PTV  D99% -0.8%  ±  1.1%  versus  -2.1%  ±  2.7%;  
CTV  D99% -0.6%   ±  0.8%   versus   -0.6%   ±  1.1%;   rectum   V65%  1.6%   ±  
7.9%   versus -1.2% ± 18%; and bladder V65% 0.5% ± 4.4% versus -0.0% ± 
9.2% (P<.001 for all dose-volume results). 
Conclusion: This study shows that MLC tracking improves the consistency 
between the planned and delivered doses compared with the modeled doses without 
MLC tracking. The implications of this finding are potentially improved patient 
outcomes, as well as more reliable dose-volume data for radiobiological parameter 
determination.  
 
 
 
 
 
 
Introduction 
 
Dynamic multileaf collimator (MLC) tracking has been developed as a real-time 
adaption technique for improving the accuracy of radiation therapy treatment 
delivery and has undergone extensive preclinical development (1). Aspects of the 
development have included assessment of the geometric (2) and dosimetric 
accuracy, quality assurance processes (3), and compatibility with Varian (2), Elekta 
(4), and Siemens (5) treatment machines. Multileaf collimator tracking has been 
developed for use with different treatment techniques, such as intensity modulated 
radiation therapy (6) and volumetric modulated arc therapy (VMAT) (7), and with 
various tumor localization systems, including megavoltage imaging (8), kilovoltage 
(kV) imaging (9), and electromagnetic transponder  tracking (10). 
A requirement for the clinical implementation of MLC tracking is an integrated 
real-time tumor localization system. One of these systems routinely used for 
observation of the prostate position during treatment is the Calypso electromagnetic 
transponder tracking system (Varian Medical Systems). Many of the preclinical 
MLC tracking studies to date involved the integration and development of the 
Varian Calypso localization system with the real-time MLC tracking system (6, 10). 
Application of real-time adaptation necessitates innovative solutions for treatment 
delivery validation, and dose reconstruction methods have been developed to be 
used as a posttreatment quality assurance step for clinical implementation of MLC 
tracking (11, 12). Dose reconstruction techniques allow the calculation of dose after 
each treatment fraction to provide an estimate of the treated dose delivered to the 
patient. In this study, dose reconstruction was performed for the majority of 
fractions for 15 patients on the first prospective clinical MLC tracking trial. The 
reconstructed doses were used to test the hypothesis that MLC tracking improved 
the agreement between the planned and delivered doses for prostate cancer radiation 
therapy treatments. 
 
  
 Methods and Materials 
 
The ethics, governance, legal, and regulatory processes were completed before the 
initiation of the clinical trial. Ethical and regulatory approval (Australian Therapeutic 
Goods Administration) was established for the use of Calypso Research Mode (Varian 
Medical Systems).  
 
Clinical trial 
 
The first prospective clinical trial implementing Calypso- guided MLC tracking 
commenced in November 2013 (NCT02033343) (13). The primary endpoint of the 
prostate trial was the successful implementation of MLC tracking for at least 95% of all 
fractions. Secondary endpoints include the assessment of the delivered dose and modeling 
of radiobiological effects. Patients eligible for the trial were those undergoing external 
beam radiation therapy for histologically proven prostate adenocarcinoma, with and 
without nodal dose coverage and prostate gross tumor volume (GTV) (defined by MRI, 
clinical examination, and biopsy positivity). The patient also had to meet the body habitus 
criteria for the use of the Varian Calypso system for tracking and to be able to have the 
Calypso beacons placed in the prostate. All patients gave written consent to participate in 
the study. 
The characteristics of the 15 patients are shown in  Table 1. There were 2 main treatment 
fractionation schedules used for the trial. Five patients received the conventional 
fractionation schedule of 80 Gy in 40 fractions, with 95% of the prescribed dose to be 
delivered to 100% of the planning target volume (PTV). Any defined GTVs were allowed 
to receive 110% of the prescribed dose.  
Six patients were selected to receive the second fractionation schedule, designed to mimic 
high-dose-rate brachytherapy boost followed by external beam radiation therapy. The 
patients received 2 10-Gy boost fractions 1 week apart, followed by 46 Gy delivered in 
daily 2-Gy fractions. The prescription for the boost part was a PTV V20Gy of at least 95%, 
and any defined GTV was prescribed 25 Gy. All patients were planned for the boost, with 
a catheter in situ. The catheter with a 2-mm margin was limited to receive 5% of the 
prescription dose to 100% of the volume and 50% of the urethra to receive <18 Gy. 
Two of the first 15 patients received altered fractionation schedules. One patient, after 
receiving 1 fraction of 10 Gy, experienced urinary retention, a grade 3 complication, and 
for this reason the second 10-Gy fraction was not delivered, and the remainder of his 
treatment was changed to 60 Gy in 30 fractions. Another patient on the boost fractionation 
schedule was diagnosed with an unrelated condition requiring him to finish treatment 
early. For this reason the patient fractionation schedule changed to 20 Gy in 2 fractions, 32 
Gy in 16 fractions, and 12 Gy in 4 fractions. 
 
Planning and treatment 
 
Planning 
All MLC tracking treatments were planned using Eclipse 11.1.47 (Varian Medical 
Systems) for delivery on a Varian Trilogy linear accelerator with Millenium120 MLC. The 
 plans were dual arc VMAT 6-MV photons. The margins for the standard 2-Gy fractions 
were not changed from the regular standard margins of 7 mm with 5 mm posterior. 
Margins for the fractions of 10 Gy were 5 mm with 3 mm posterior. Once plans were 
completed to fit dose constraints and prescriptions, alterations were made to the plans to 
allow the implementation of MLC tracking. Each of the collimator jaws were opened a 
further 8 mm to allow the real-time movement of the MLC aperture without moving 
beneath the collimator jaws. To account for this extra area, the plan was renormalized and 
the coverage and dose constraints reassessed. A copy of the MLC file was created for each 
treatment arc; the files contain MLC positions as a function of gantry angle along with 
patient identifiers and were used as input into the MLC tracking software at the time of 
treatment. Once all alterations were made, the planned dose was again assessed and 
patient-specific quality assurance (portal dose delivery with and without MLC tracking 
with zero motion file) was performed. 
 
Setup and treatment 
Patients were positioned and set up using the Calypso localization system, and for the 2-
Gy fractions standard kV/ kV or cone beam computed tomography (CBCT) were not 
routinely acquired. For the fractions of 10 Gy, the patients received an enema 1 hour before 
treatment, and 5 of the 6 patients who received boost fractions were catheterized for these 
deliveries. The patients were set up with Calypso, and a CBCT was then obtained and 
compared with the Calypso information by a clinician at the treatment console. The 
urethral and target positions were checked, and the treatment was approved by the 
physician. At setup, if the target rotation was greater than 10o, a CBCT was obtained and 
an assessment performed using an overlay of the planned structures to ensure the prostate 
was within the target volume before beginning treatment. 
Once the patient was set up and the treatment field was ready, the MLC tracking software 
was connected. The software had input of the real-time Calypso position (research mode) 
information and the treatment field MLC file obtained from the patients’ treatment plan 
containing all MLC positions in respect to gantry angle. Once the MLC tracking software 
was connected, it assumed control over the MLC controller and, by combining the planned 
MLC positions with the real-time location of the target, calculated new MLC positions and 
continually sent these to the treatment machine. 
Before each treatment arc the motion of the prostate was assessed, and if the displacement 
was >2.5 mm in any direction, a couch shift was applied from Calypso to return the target 
to the planned position. During the treatment arcs, a beam hold results when displacement 
of the target exceeds 8 mm in any of the 3 patient dimensions (via Calypso) or in the 
beams-eye view (via MLC tracking). If the excursion was persistent, the couch would be 
shifted to return the target to the planned position and the treatment resumed. 
Data collected during the treatment include the Calypso observed prostate motion 
trajectory and the treatment machine log files, which contain the treatment MLC positions 
as well as gantry and dose information. 
 
 
Dose reconstruction 
 
 After each treatment fraction, an isocenter shift dose reconstruction method (12) was used 
to determine the treated dose delivered to the patient with MLC tracking and the modeled 
dose that would have been delivered without MLC tracking (Fig. 1). The plan 
corresponding to the treated dose (with MLC tracking) was created using an in- house 
MATLAB (R2013b) program by combining the patient’s original treatment plan and dose 
with the observed prostate motion (translation only) and the treatment MLC positions 
collected during the fraction delivery. This treatment plan was then imported into the 
treatment planning system (Eclipse 11.1.47) and treated dose calculated for comparison 
with the patient’s original planned dose. 
The same dose reconstruction method was used to create the modeled dose plan without 
MLC tracking; however, the MLC positions from the patient’s original treatment plan 
were used rather than the treatment MLC positions. The without-MLC tracking plan was 
imported into the treatment planning system and calculated for comparison with the 
original planned dose. 
Statistical analysis 
Dose-volume histograms for the clinical target volume (CTV), PTV, rectum, and bladder 
were computed from both the treated and without-MLC tracking dose distributions for 
each individual fraction, along with those of the patient’s original planned dose 
distribution. The hypothesis that MLC tracking improves the consistency between the 
planned and treated with MLC tracking values over that without MLC tracking was tested 
for each dose-volume value via analysis of variance using the F test. The non- normality of 
the dose-volume points was confirmed using the Kolmogorov-Smirnov test. 
 
  
 Results 
 
For the 15 patients in the study, 513 fractions were deliv- ered, all successfully with MLC 
tracking. One of the tracking patients was unable to be set up at the planning isocenter 
owing to body habitus and so was treated with an offset of approximately 3 mm with MLC 
tracking for 21 of the 40 fractions. These 21 fractions were not used for either the motion 
or dose reconstruction analysis. A further 17 fractions over the patient cohort were not 
used for motion or dose reconstruction analysis owing to machine faults, unrelated to MLC 
tracking, resulting in the data files created during the delivery not being compatible with 
the dose reconstruction software. 
 
Intrafraction motion 
Statistics of the prostate motion while the treatment beam was on for 475 fractions show 
that the average mean displacement for the fractions was 1.4 mm, with the highest mean 3-
dimensional (3D) displacement for an individual fraction of 6.4 mm. The total percentage 
of treatment time that the displacement of the target was above 3, 5, 7, and 10 mm for all 
475 fractions was 4%, 0.7%, 0.3%, and 0%, respectively. The maximum percentage of 
time the target moved further than 3, 5, 7, and 10 mm for individual fractions was 96%, 
66%, 45%, and 4.7%, respectively. Although 3D displacements of >8 mm were observed, 
motion exceeding 8 mm in any of the 3 patient dimensions or those of the beams-eye view 
did not occur, and therefore no beam holds were asserted.  The mean  3D   displacement  
for   95%  of  the  fractions   was <2.5 mm, and only 8 of the 475 fractions had a mean 
displacement >3 mm, as can be seen in Figure 2. 
 
Dose reconstruction comparison 
 
Dose reconstruction was performed for 460 2-Gy fractions, 11 boost (10-Gy) fractions, and 
4 3-Gy fractions. 
For each individual fraction, 3 dose distributions were compared. Figure 3 compares these 
different dose distributions for a single (2-Gy) fraction, with a mean displacement and 
standard deviation of 3.6  ±   3.3 mm and a range of 0.5-9.2 mm. The reconstructed treated  
dose (with MLC tracking) (center) and the reconstructed without-MLC tracking dose 
(right) were both compared with the original planned dose (left). Using a dose-volume 
histogram (Fig. 4), the percentage difference from the planned value for dose-volume 
points PTV  D99%,  CTV D99%, rectum V65%, and bladder V65% was  calculated.  For this 
individual fraction the difference from the planned PTV D99%, CTV D99%, rectum V65%,  
and  bladder  V65% values were 0.05%, - 1.7%, 9.1%, and - 3.0%, respectively, for the 
treated dose and  - 18.1%,   - 7.9%, 41.3%,   and - 33.4% for the without-MLC tracking  
dose  distribution. 
The mean difference and standard deviation for all 475 individual fractions for PTV 
D99% of the treated (with MLC tracking) from the planned PTV D99% was - 0.8% 
±1.1% (Fig. 5a). Without MLC tracking, the mean difference and standard deviation 
from planned for the same dose-volume point was - 2.1% ± 2.7%. The CTV D99% 
mean and standard deviation for the treated and the without-MLC tracking   dose   
distributions   were   -0.6%   ±  0.8%   and -0.6%  ±  1.1%,  respectively.  For  the  organs  
at  risk,  the dose-volume points of the rectum V65% and bladder V65% were assessed 
 
(Fig. 5b), with the mean and standard deviation from planned of the treated dose being 
1.6% ±  7.9% and 0.5% ±  4.4%, respectively, and for the without-MLC tracking 
doses, - 1.2% ± 18% and 0.0 ± 9.2%, respectively. The P value for all dose-volume 
points for 475 fractions was <.001. 
The   average   mean   displacement   for   the   9 treated 10-Gy fractions alone was 1.4 
mm. The mean and standard deviation from planned for the PTV D99% treated and 
without-MLC tracking doses were 0.2% ± 1.8% and - 0.9% ± 2.9%, respectively. The 
CTV D99% mean and standard deviations from  planned  for  the  treated and without-
MLC tracking doses were 0.2% ± 1.2% and 0.3% ± 0.8%, respectively. The rectum 
V65% and bladder V65% mean and standard deviation of the treated dose from planned 
were -19.4% ± 20% and 9.4% ± 16%. For the without-MLC tracking dose, the values  
were -21.2% ± 45% and 12.6% ± 37%. All 4 sets of data for the PTV and CTV were 
found to be normally distributed, whereas the rectum and bladder data were not. The 
difference invariance from planned for the PTV and CTV data was not significant, 
with  P=.08  and  P=.12. The normal tissues were found to have a significant dif 
ference in variance from planned for treated versus without-MLC tracking, with 
P=.01 and P=.006, respectively. 
 
Discussion 
 
Multileaf collimator tracking has been implemented for the first time in a prospective 
prostate cancer clinical trial. The results of this study show that the treated doses of MLC 
tracking treatments vary less from the planned dose than the equivalent treatment 
deliveries modeled without MLC tracking for prostate cancer radiation therapy. 
This study shows that MLC tracking can reduce the variance from the planned dose to that 
which is delivered to the patient. These prospective results are consistent with a 
retrospective preclinical MLC tracking dose reconstruction study (11). A simulation study 
performed using dose reconstruction for conventional and subvolume boost treatments for 
prostate showed that MLC tracking is effective at mitigating the dosimetric effects of 
prostate motion and allows for successful GTV and PTV dose delivery (14), as 
demonstrated in the present study. The dosimetric results for the without-MLC tracking 
delivery also corresponds closely with other observational prostate dose reconstruction 
studies (15, 16) that have modeled the effect of intrafraction prostate motion on the dose 
delivery of standard non-MLC tracking treatments. The outlier fractions for which the dose 
distribution was improved by MLC tracking tended to be lower PTV and CTV doses, 
lower rectum doses, and higher bladder doses. The normal tissue variations are likely due 
to the drift of the prostate for some fractions in the posterioreinferior direction due to 
bladder filling: the posterior wall of the bladder shifts into a higher dose region, whereas 
the rectum is shifted away (17). The large range of results for the rectum and bladder 
appear because the percentage change is assessed in relation to the planned percentage of 
the organ volume receiving 65% of the prescription dose and not the entire organ. 
The dosimetric results show that tracking had little effect on the mean difference from the 
planned doses; it did, however, reduce the effect of outlier fractions with large underdoses 
of the targets. This increased certainty in de- livery accuracy will allow for the possibility 
of reducing margins for prostate treatments and enable more consistent delivery of SBRT 
prostate treatments. 
The prostate motions measured during treatment for this study are similar to other 
 
observational study results (17, 18), with a similar percentage of fractions with high mean 
displacements of >3 mm. The data from this study do show a greater percentage of 
fractions with a mean displacement in the 1- to 3-mm range and fewer in the 0- to 1-mm 
range. This is likely due to several factors: previous studies did not correct for patient 
motion after the initial setup or imaging; 1 study assessed all motion relative to the initial 
setup image position rather than the planned position (18); and throughout the present 
study couch corrections were made and the patient position shifted when the prostate 
moved >2.5 mm (as observed by Calypso) in any of the 3 dimensions before the first arc 
and between treatment arcs. This means that the prostate motion of this study has a slightly 
different displacement distribution but is still comparable to other prostate motion data. 
Because of the pre- and inter-arc couch corrections during some fraction deliveries, the 
dose distributions of these modeled fractions, without MLC tracking, likely underestimate 
the dosimetric variability present for regular standard of care, in which correction is made 
to patient position after initial imaging. These fractions are more consistent with the 
scenario in which an inter-arc patient position correction is performed. 
A limitation of this first implementation of MLC tracking is that it only corrects for 
translation of the target volume and does not account for either rotation or deformation. 
This limitation is mirrored in the dose reconstruction process (12) and will likely be 
mitigated in the future with further development of the MLC tracking technology to 
account for rotation and deformation (19, 20). This increase in information obtained 
during treatment would also help to inform dose reconstruction for better estimates of 
delivered treated doses. This issue also leads to another limitation of the dose 
reconstruction process that models the organs at risk (eg rectum and bladder) motion with 
the same trajectory as the target volume, with no deformation or volume changes 
accounted for. 
 
Conclusions 
 
Multileaf collimator tracking has been implemented clinically for the first time in a 
prostate cancer VMAT trial. The application of MLC tracking was shown to improve the 
consistency between the planned and delivered doses compared with doses that would 
have been delivered without MLC tracking. The implications of this finding are potentially 
improved patient outcomes, reduced margins for future studies, and more reliable dose-
volume data for radiobiological parameter determination. Multileaf collimator tracking is 
translatable to other tumor types as an effective motion management strategy. Future 
research will develop and translate to clinical practice solutions to tumor rotation and 
deformation, including differential motion of multiple targets. 
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Table 1. Patient Cohort 
Table 1. Patient cohort 
Characteristic Value 
Age (y) 69 (57-81) 
PSA (ng/mL) 10.9 (1.1-33) 
Gleason score 9 (7-10) 
Clinical staging 
 T1CN0M0 4 
 T2AN0M0 3 
 T2BN0M0 3 
 T2CN0M0 1 
 T2N1M0 1 
 T3AN0M0 1 
 T3BN0M0 2 
Fractionation schedules 
 80 Gy/40 Fx 9 
 20 Gy/2 Fx + 46 Gy/23 Fx 4 
 Altered fractionation∗ 2 
PTV volume (cm3) 132 (62-185) 
Abbreviations: Fx = treatment fraction; PSA = prostate-specific antigen; PTV = planning target volume. 
Values are number or median (range). 
∗ 
10 Gy/1 Fx + 60 Gy/30 Fx; 20 Gy/2 Fx + 32 Gy/16 Fx + 12 Gy/4 Fx. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Dose comparison process for individual fractions; separate treated 
doses (with multileaf collimator [MLC] tracking) and without-MLC tracking 
doses are created using dose reconstruction and compared with the original 
planned dose. The treated dose is created by combining the original treatment 
plan with the observed prostate motion during treatment and the treatment 
MLC positions, whereas the without-MLC tracking dose is created by 
combining the original treatment plan and observed prostate motion alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Frequency histogram of the mean displacement for 475 multileaf 
collimator tracking treatment fractions 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The 3 dose distributions (≥95% isodose) for a single 2-Gy 
fraction with a mean displacement of 3.6 mm with the planning target 
volume (red) and contoured gross tumor volume (blue). The planned dose 
distribution (left), the treated with MLC tracking dose (center), and the 
modeled without multileaf collimator (MLC) tracking dose (right).  
 
 
 
 
Figure 4. Comparison of dose-volume histograms for the dose distributions 
in Fig. 3 of a 2-Gy fraction with a mean displacement of 3.6 mm. The 
planned dose (solid line), the treated with MLC tracking dose (dashed 
line), and the modeled without MLC tracking dose (dotted line). 
CTV = clinical target volume; PTV = planning target volume. 
 
 
 
 
 
 
 
 
Fig. 5. The calculated percentage dose difference (n=475) from the planned value for the 
treated (blue) and without multileaf collimator tracking (red) dose distributions for (a) 
planning target volume (PTV) and clinical target volume (CTV) D99% values, and (b) 
rectum and bladder V65% values. Represented by median and 25th and 75th percentile. 
Vertical lines indicate the maximum and minimum values.  
 
 
